{"id":893671,"date":"2025-10-08T08:23:38","date_gmt":"2025-10-08T12:23:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-capital-and-subsidiary-cyncado-therapeutics-pioneer-convergence-of-digital-assets-and-oncology-innovation-exploring-tokenization-framework-for-mesothelioma-program-as-it-advances-toward-q1-2\/"},"modified":"2025-10-08T08:23:38","modified_gmt":"2025-10-08T12:23:38","slug":"alphaton-capital-and-subsidiary-cyncado-therapeutics-pioneer-convergence-of-digital-assets-and-oncology-innovation-exploring-tokenization-framework-for-mesothelioma-program-as-it-advances-toward-q1-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-capital-and-subsidiary-cyncado-therapeutics-pioneer-convergence-of-digital-assets-and-oncology-innovation-exploring-tokenization-framework-for-mesothelioma-program-as-it-advances-toward-q1-2\/","title":{"rendered":"AlphaTON Capital and Subsidiary Cyncado Therapeutics Pioneer Convergence of Digital Assets and Oncology Innovation: Exploring Tokenization Framework for Mesothelioma Program as it Advances Toward Q1 2026 First Patient Dosing"},"content":{"rendered":"

\nLandmark Initiative Positions AlphaTON at Forefront of Decentralized Science (DeSci) Movement, Leveraging TON Infrastructure to Accelerate Life-Saving Cancer Research
\n<\/h2>\n
\n

Dover, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) — AlphaTON Capital<\/a> Corp (Nasdaq: ATON) (“AlphaTON” or the “Company”), alongside its wholly owned oncology subsidiary Tarus Therapeutics, LLC (dba Cyncado Therapeutics) (“Cyncado”), today announced a groundbreaking non-binding letter of intent (LOI) to evaluate tokenization of single-indication economics for TT-4 in mesothelioma, representing a transformative step in merging institutional-grade digital asset infrastructure with breakthrough cancer therapeutics.<\/p>\n

This pioneering initiative exemplifies AlphaTON’s unique position as the only Nasdaq-listed company simultaneously operating a strategic TON token treasury and advancing potentially first-in-class immunotherapy assets. The Company is leveraging decentralized science (DeSci) principles and web3 infrastructure to reimagine how life-saving medical research is funded, accelerated, and brought to patients globally.\u00a0<\/p>\n

\n Bridging Two Frontiers: Digital Assets Meet Life-Saving Science<\/b>\n <\/p>\n

AlphaTON’s strategic vision unites two high-impact domains previously operating in parallel: the Company’s comprehensive TON ecosystem operations – including validator services, network staking, and Telegram-based application development serving over one billion users – with Cyncado’s clinical-stage pipeline targeting immune checkpoint resistance in deadly cancers.<\/p>\n

“We are witnessing the birth of a new paradigm in biomedical innovation,” said Brittany Kaiser, Chief Executive Officer of AlphaTON Capital. “By thoughtfully integrating our digital asset capabilities with Cyncado’s compelling oncology programs, we’re not just exploring novel financing mechanisms, we’re pioneering the future of decentralized science. This approach has the potential to democratize access to groundbreaking cancer research, accelerate development timelines, and create unprecedented alignment between global stakeholders and patient outcomes.”<\/p>\n

The mesothelioma tokenization initiative represents the first step in what could become a transformative model for funding and advancing therapeutic development through decentralized infrastructure, while preserving all traditional partnership, licensing, and exit pathways. Coupled with TON\u2019s infinite sharding paradigm (ISP) data architecture, this new advancement not only has the opportunity to safeguard quality of life for patients, but also HIPAA-compliant data ownership and security for sensitive clinical on-chain data applications.<\/p>\n

\n Clinical Momentum: TT-4 Advancing Toward Patients in Q1 2026<\/b>\n <\/p>\n

Cyncado has confirmed it is in final clinical start-up preparations for TT-4, an oral, ultra-selective A2B receptor antagonist, with first-patient dosing targeted for Q1 2026. The drug will initially enter a safety dose-escalation cohort enrolling solid tumor patients under Cyncado’s existing FDA-cleared TT-10-101 (ADPORT-601) protocol, with a larger mesothelioma-focused study planned immediately thereafter at major U.S. cancer centers.<\/p>\n

Mesothelioma, an aggressive cancer primarily caused by asbestos exposure, represents a significant unmet medical need with limited treatment options and poor prognosis. TT-4’s preclinical data demonstrate compelling potential:<\/p>\n